These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37664582)

  • 1. Minimal mRNA uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human placental explants.
    Gonzalez VJ; Li L; Buarpung S; Prahl M; Robinson JF; Gaw SL
    iScience; 2023 Sep; 26(9):107549. PubMed ID: 37664582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal mRNA uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human placental explants.
    Gonzalez V; Li L; Buarpung S; Prahl M; Robinson JF; Gaw SL
    medRxiv; 2023 Feb; ():. PubMed ID: 36778281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Adverse Reactions, Antibody Patterns, and 12-month Outcomes in the Mother-Infant Dyad After COVID-19 mRNA Vaccination in Pregnancy.
    Cassidy AG; Li L; Golan Y; Gay C; Lin CY; Jigmeddagva U; Chidboy MA; Ilala M; Buarpung S; Gonzalez VJ; Basilio E; Duck M; Murtha AP; Wu AHB; Lynch KL; Asiodu IV; Prahl MK; Gaw SL
    JAMA Netw Open; 2023 Jul; 6(7):e2323405. PubMed ID: 37450302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Skawran S; Gennari AG; Dittli M; Treyer V; Muehlematter UJ; Maurer A; Burger IA; Mader C; Messerli O; Grünig H; Gebhard C; Huellner MW; Curioni-Fontecedro A; Berger C; Messerli M
    Eur Radiol; 2022 Jan; 32(1):508-516. PubMed ID: 34156552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
    Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
    Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
    Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
    BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
    Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
    Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Maternal and Neonatal Antibody Levels After COVID-19 Vaccination vs SARS-CoV-2 Infection.
    Flannery DD; Gouma S; Dhudasia MB; Mukhopadhyay S; Pfeifer MR; Woodford EC; Briker SM; Triebwasser JE; Gerber JS; Morris JS; Weirick ME; McAllister CM; Hensley SE; Puopolo KM
    JAMA Netw Open; 2022 Nov; 5(11):e2240993. PubMed ID: 36350652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis.
    Yau K; Chan CT; Abe KT; Jiang Y; Atiquzzaman M; Mullin SI; Shadowitz E; Liu L; Kostadinovic E; Sukovic T; Gonzalez A; McGrath-Chong ME; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Levin A; Blake PG; Colwill K; Gingras AC; Hladunewich MA
    CMAJ; 2022 Feb; 194(8):E297-E305. PubMed ID: 35115375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and Characteristics of Nodal and Deltoid FDG and
    Schroeder DG; Jang S; Johnson DR; Takahashi H; Navin PJ; Broski SM; Thorpe MP; Johnson GB; Young JR
    AJR Am J Roentgenol; 2021 Nov; 217(5):1206-1216. PubMed ID: 34009000
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
    Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.